长期小剂量阿奇霉素治疗支气管扩张症的疗效

Abstract
Figure/Table
References (18)
Related Citation (14)

Download: PDF (944 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the curative effect of long-term low-dose azithromycin in the treatment of bronchiectasis. Methods A total of 98 patients with bronchiectasis admitted to Inner Mongolian Autonomous Regional Corps Hospital of Chinese People's Armed Police Force from June 2021 to March 2024 were divided into a control group and an observation group, with 49 cases in each group according to random number table method, The control group received conventional symptomatic treatment, while the observation group received long-term low-dose azithromycin treatment on the basis of the control group. After 6 months, the clinical efficacy, dyspnea, sputum characteristics and airway inflammation were compared between the two groups. Results After treatment, the total effective rate of the observation group was 91.84%, which was higher than that of the control group (75.51%) (P<0.05). The Saint George's Respiratory Questionnaire (SGRQ) score of the observation group was (44.33±13.69), which was lower than that of the control group (58.88±14.29). The modified Medical Research Council Dyspnea Scale (mMRC) score was (2.08±0.40), which was lower than that of the control group (2.71±0.46). The differences were statistically significant (P<0.05). The 24-hour sputum volume of the observation group was lower than that of the control group, and the sputum density and purulent mucus scores were lower than those of the control group. The expressions of sputum interleukin-6 (IL-6), 65 subunit protein (p65) and high-sensitivity C-reactive protein (hs-CRP) were lower than those of the control group. The differences were statistically significant (P<0.05). Conclusions The clinical value of long-term low-dose azithromycin treatment for bronchiectasis is significant, which is helpful to improve the curative effect of patients, relieve the degree of dyspnea, and promote the improvement of sputum characteristics and airway inflammation.

Key words： bronchiectasis low dose azithromycin dyspnea sputum characteristics airway inflammation

Received: 31 October 2024

ZTFLH:

R969

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Xiaohua
	PIAO Yuxin
	CHAI Wenqiang
	FAN Chaoyu
	LI Dawen

Cite this article:

LIU Xiaohua,PIAO Yuxin,CHAI Wenqiang等. Curative effect of long-term low-dose azithromycin in treatment of bronchiectasis[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(2): 106-109.

URL:

https://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR https://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2025/V36/I2/106

[1]	Martinez-Garcia M A, Posadas T, Sotgiu G, et al. Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials[J].Resp Med,2020,172(9):106127-106127.
[2]	刘学东,赵伟业,张淑立,等.成人支气管扩张症的研究进展[J].中华结核和呼吸杂志,2020,43(10):902-905.
[3]	程克斌,徐金富,李惠萍,等.支气管扩张症的免疫调节机制及其免疫调节治疗进展[J].国际呼吸杂志,2019,39(6):457-461.
[4]	林继雷,郑雪香,钟林平,等.小剂量阿奇霉素辅助治疗儿童闭塞性细支气管炎临床疗效分析[J].儿科药学杂志,2019,25(1):18-20.
[5]	支气管扩张症专家共识撰写协作组,中华医学会呼吸病学分会感染学组.中国成人支气管扩张症诊断与治疗专家共识[J].中华结核和呼吸杂志,2021,44(4):311-321.
[6]	成人支气管扩张症诊治专家共识编写组,成人支气管扩张症诊治专家共识(2012版)[J].中华危重症医学杂志电子版,2012,5(5):315-328.
[7]	RhaziK E,Nejjari C,Benjelloun M C,et al.Validation of the St.George's respiratory questionnaire in patients with COPD or asthma in Morocco[J].Int J Tuberc Lung D,2006,10(11):1273-1278.
[8]	Bestall JC, Paul EA, Garrod R, et al. Usefulness of the medical research council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease[J].Thorax,1999,54(7):581-586.
[9]	刘英彦,张民,崔剑,等.雾化吸入乙酰半胱氨酸溶液联合振动机械排痰治疗重型颅脑损伤后坠积性肺炎效果观察[J].山东医药,2020,60(11):62-64.
[10]	宋元林,侯东妮.支气管扩张症患者气道肠道微生态的研究及临床价值[J].诊断学理论与实践,2019,18(5):503-508.
[11]	朱倩,陈霞,包宇航.长期小剂量阿奇霉素治疗稳定期支气管扩张症疗效与安全性的系统评价[J].中国医院用药评价与分析,2019,19(6):734-737,741.
[12]	Hill A T,Sullivan A L,Chalmers J D,et al.British thoracic society guideline for bronchiectasis in adults[J]. Thorax,2019,74(1):1-69.
[13]	崔涛,马姣,石芳,等.不同剂量阿奇霉素维持治疗稳定期COPD患者的临床疗效[J].中国老年学杂志,2022,42(11):2693-2696.
[14]	王友梅,陈鹏,郭兴法,等.阿奇霉素联合双黄连颗粒对支原体肺炎患儿免疫功能及肺表面活性物质相关蛋白-D水平的影响[J].中国妇幼保健,2019,34(24):5634-5637.
[15]	刘娜,朱剑楠,林勇.阿奇霉素联合支气管肺泡灌洗对支气管扩张症患者肺功能、灌洗液炎性因子水平的影响[J].中国临床医生杂志,2020,48(12):1417-1419.
[16]	Bacharier L B.Azithromycin during wheezing illnesses among preschool children:does the airway microbiota provide insights into mechanism[J].Am J Respir Crit Care Med,2021,204(2):115-116.
[17]	刘宪河.支气管肺炎患儿血清hs-CRP,IL-6和TNF-α水平变化及临床意义[J].河北医药,2019,41(1):99-102.
[18]	杨宇杰,陈大兴,潘华峰,等.阿奇霉素干混悬剂联合左氧氟沙星氯化钠注射液治疗慢性支气管炎及对TNF-α,IL-6的影响[J].广东医学,2019,40(6):834-837.